

## Diabetes remission and nonalcoholic fatty pancreas disease

Wen-Jun Wu

**Specialty type:** Endocrinology and metabolism

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade C

**Novelty:** Grade C

**Creativity or Innovation:** Grade B

**Scientific Significance:** Grade C

**P-Reviewer:** Ghusrn W, United States

**Received:** January 22, 2024

**Revised:** March 13, 2024

**Accepted:** April 9, 2024

**Published online:** July 15, 2024

**Processing time:** 168 Days and 2 Hours



**Wen-Jun Wu**, Department of Endocrinology, Jinshan Branch of Shanghai Sixth People's Hospital, Shanghai 201500, China

**Corresponding author:** Wen-Jun Wu, MD, Adjunct Associate Professor, Chief Doctor, Department of Endocrinology, Jinshan Branch of Shanghai Sixth People's Hospital, No. 147 Jiankang Road, Zhujing Town, Jinshan District, Shanghai 201500, China.  
[wuwenjung@163.com](mailto:wuwenjung@163.com)

### Abstract

This editorial focuses on the relationship between nonalcoholic fatty pancreas disease (NAFPD) and the development and remission of type 2 diabetes (T2D). NAFPD is characterized by intrapancreatic fatty deposition associated with obesity and not associated with alcohol abuse, viral infections, and other factors. Ectopic fat deposition in the pancreas is associated with the development of T2D, and the underlying mechanism is lipotoxic  $\beta$ -cell dysfunction. However, the results on the relationship between intrapancreatic fat deposition (IPFD) and  $\beta$ -cell function are conflicting. Regardless of the therapeutic approach, weight loss improves IPFD, glycemia, and  $\beta$ -cell function. Pancreatic imaging is valuable for clinically monitoring and evaluating the management of T2D.

**Key Words:** Diabetes remission; Type 2 diabetes; Pancreatic fat content;  $\beta$  cell function; Weight loss

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Excess fat in the pancreas impairs  $\beta$ -cell function. The remission of type 2 diabetes and the improvement of  $\beta$ -cell function are achieved by decreasing intrapancreatic fat deposition during weight loss.

**Citation:** Wu WJ. Diabetes remission and nonalcoholic fatty pancreas disease. *World J Diabetes* 2024; 15(7): 1390-1393

**URL:** <https://www.wjgnet.com/1948-9358/full/v15/i7/1390.htm>

**DOI:** <https://dx.doi.org/10.4239/wjd.v15.i7.1390>

## INTRODUCTION

The remission of type 2 diabetes (T2D) is achievable despite the need for drug therapy. In clinical practice, T2D remission is defined as glucose levels lower than the thresholds established by the World Health Organization and the American Diabetes Association for 3 months without glucose-lowering pharmacotherapy[1]. Several interventions can effectively achieve T2D remission, including nutrition and weight management, pharmacotherapy, and bariatric surgery[2-4]. The mechanism shared by these therapeutic approaches is the improvement of  $\beta$ -cell function, especially first-phase insulin secretion (FPIS)[5].  $\beta$  cells, located in the pancreatic islets of Langerhans, secrete insulin in response to an increase in postprandial glucose levels. Glucose-stimulated insulin secretion occurs in an early phase and a late phase, characterized by fast and slow secretory activity, respectively. FPIS dysfunction is an early marker of  $\beta$ -cell dysfunction during T2D progression. Studies on weight loss-induced T2D remission demonstrated that responders had shorter diabetes duration, better  $\beta$ -cell function, and less pancreatic fat at baseline than non-responders; nonetheless, there was no between-group difference in hepatic fat[6-8]. Hepatic insulin sensitivity improved regardless of the duration of diabetes, whereas  $\beta$ -cell dysfunction increased with the duration of diabetes[7]. Weight loss was positively associated with diabetes remission[9, 10]. Weight loss can decrease excess fat deposition in the liver and pancreas, reduce insulin resistance, and restore  $\beta$ -cell function; the reverse is also true[8,11]. This evidence supports Taylor's twin-cycle hypothesis and suggests that the capacity to regain  $\beta$ -cell function may be related to intrapancreatic fat deposition (IPFD) and duration of diabetes.

## IPFD AND $\beta$ -CELL FUNCTION

Animal studies *in vitro* and *in vivo* demonstrated that IPFD impaired  $\beta$ -cell function[12]. Moreover, there is evidence that lipotoxic  $\beta$ -cell dysfunction occurs in humans. A meta-analysis of cross-sectional studies showed that nonalcoholic fatty pancreas disease (NAFPD) was associated with a significantly greater risk of T2D[13]. Of four longitudinal studies, three showed that NAFPD increased T2D incidence[14-17]. Magnetic resonance imaging (MRI) showed that T2D was associated with decreased pancreatic volume, IPFD, and pancreas with irregular borders[18]. Moreover, pancreatic morphology changed as T2D progressed. Other studies found that a 6-month remission of T2D was related to less irregularity in pancreatic borders and no increase in pancreatic volume[19], and a 2-year remission of T2D was associated with regular borders and restoration of the pancreatic volume[20].

The correlation between IPFD and  $\beta$ -cell function is unclear. Some studies demonstrated that IPFD affects  $\beta$ -cell function in patients with glucose tolerance[21-23]. Other studies found no link between IPFD and  $\beta$ -cell function[24-26]. One explanation for the conflicting results is cohort differences in age, ethnicity, glucose metabolic status, and the duration of diabetes. After controlling for age, T2D duration, and the effects of drug therapy, pancreatic fat quantified by MR Dixon imaging revealed that IPFD correlated negatively with  $\beta$ -cell function[27]. Furthermore, a longitudinal study showed that IPFD was linked to lower insulin secretory capacity in patients with T2D[28]. Weight loss also decreased IPFD in T2D and was associated with increased insulin secretory capacity[29,30]. Thus, IPFD influences  $\beta$ -cell function.

The mechanism by which IPFD affects  $\beta$ -cell function is lipotoxicity. Evidence from cellular and animal models demonstrated that IPFD inhibited insulin secretion and caused the atrophy of  $\beta$ -cells[31]. The detailed molecular mechanisms include oxidative and endoplasmic reticulum stress, mitochondrial dysfunction, hypertriglyceridemia, and an increase in proinflammatory factors.

## CLINICAL IMPLICATIONS

Early diagnosis and treatment to preserve and restore  $\beta$ -cell function are clinically important for T2D remission. Pancreatic morphology and IPFD are closely related to  $\beta$ -cell function. Thus, imaging-based fat quantification is recommended during routine clinical examination for two reasons. First, T2D is often accompanied by decreased pancreatic volume, IPFD, and pancreas with irregular borders. Second, weight loss and the consequent intrapancreatic fat loss are essential for T2D remission.

The fat content of the pancreas can be determined by ultrasound (US), computed tomography (CT) and MRI[32]. Despite the low cost, convenience, and wide applicability, US has low sensitivity for pancreatic fat quantification in individuals with obesity. CT is precise, and measurements are reproducible; however, ionizing radiation limits the use of CT for follow-up monitoring. MRI is safe and non-radioactive and accurately quantifies fat deposition. MRI is ideal for pancreatic fat quantification despite the high cost and long processing time.

## CONCLUSION

The epidemic of T2D and associated complications are a global health priority. T2D remission is crucial to improve the health of individuals with T2D and reduce economic and health burden.  $\beta$ -cell function is a key factor for the onset development and remission of T2D. Evidence suggests that IPFD impairs  $\beta$ -cell function and affects T2D onset more strongly than intrahepatic fat deposition. The quantification of pancreatic fat is useful for the early screening, remission prediction, and personalized management of T2D. In future, it is very essential to explore potential therapeutic approaches that target pancreatic fat reduction.

## FOOTNOTES

**Author contributions:** Wu WJ reviewed the literature and wrote the manuscript.

**Conflict-of-interest statement:** There are no potential conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Wen-Jun Wu [0000-0001-9746-8694](https://orcid.org/0000-0001-9746-8694).

**S-Editor:** Chen YL

**L-Editor:** A

**P-Editor:** Zhang YL

## REFERENCES

- Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. *Diabetes Care* 2021; **44**: 2438-2444 [PMID: [34462270](https://pubmed.ncbi.nlm.nih.gov/34462270/) DOI: [10.2337/dci21-0034](https://doi.org/10.2337/dci21-0034)]
- Churuangsu C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. *Diabetologia* 2022; **65**: 14-36 [PMID: [34796367](https://pubmed.ncbi.nlm.nih.gov/34796367/) DOI: [10.1007/s00125-021-05577-2](https://doi.org/10.1007/s00125-021-05577-2)]
- Vasdeki D, Koufakis T, Tsamos G, Busetto L, Zebekakis P, Kotsa K. Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches. *Nutrients* 2022; **14** [PMID: [36432488](https://pubmed.ncbi.nlm.nih.gov/36432488/) DOI: [10.3390/nu14224801](https://doi.org/10.3390/nu14224801)]
- Kirwan JP, Courcoulas AP, Cummings DE, Goldfine AB, Kashyap SR, Simonson DC, Arterburn DE, Gourash WF, Vernon AH, Jakicic JM, Patti ME, Wolski K, Schauer PR. Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). *Diabetes Care* 2022; **45**: 1574-1583 [PMID: [35320365](https://pubmed.ncbi.nlm.nih.gov/35320365/) DOI: [10.2337/dc21-2441](https://doi.org/10.2337/dc21-2441)]
- Suleiman M, Marselli L, Cnop M, Eizirik DL, De Luca C, Femia FR, Tesi M, Del Guerra S, Marchetti P. The Role of Beta Cell Recovery in Type 2 Diabetes Remission. *Int J Mol Sci* 2022; **23** [PMID: [35806437](https://pubmed.ncbi.nlm.nih.gov/35806437/) DOI: [10.3390/ijms23137435](https://doi.org/10.3390/ijms23137435)]
- Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* 2011; **54**: 2506-2514 [PMID: [21656330](https://pubmed.ncbi.nlm.nih.gov/21656330/) DOI: [10.1007/s00125-011-2204-7](https://doi.org/10.1007/s00125-011-2204-7)]
- Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care* 2016; **39**: 808-815 [PMID: [27002059](https://pubmed.ncbi.nlm.nih.gov/27002059/) DOI: [10.2337/dc15-1942](https://doi.org/10.2337/dc15-1942)]
- Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, Hollingsworth KG, Mathers JC, Sattar N, Lean MEJ. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for  $\beta$  Cell Recovery. *Cell Metab* 2018; **28**: 547-556.e3 [PMID: [30078554](https://pubmed.ncbi.nlm.nih.gov/30078554/) DOI: [10.1016/j.cmet.2018.07.003](https://doi.org/10.1016/j.cmet.2018.07.003)]
- Thom G, Messow CM, Leslie WS, Barnes AC, Brosnahan N, McCombie L, Al-Mrabeh A, Zhyzhneuskaya S, Welsh P, Sattar N, Taylor R, Lean MEJ. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabet Med* 2021; **38**: e14395 [PMID: [32870520](https://pubmed.ncbi.nlm.nih.gov/32870520/) DOI: [10.1111/dme.14395](https://doi.org/10.1111/dme.14395)]
- Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Snihotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2019; **7**: 344-355 [PMID: [30852132](https://pubmed.ncbi.nlm.nih.gov/30852132/) DOI: [10.1016/S2213-8587\(19\)30068-3](https://doi.org/10.1016/S2213-8587(19)30068-3)]
- Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, Barnes AC, Melhem S, Jesuthasan A, Aribisala B, Hollingsworth KG, Lietz G, Mathers JC, Sattar N, Lean MEJ, Taylor R. Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. *Cell Metab* 2020; **31**: 233-249.e4 [PMID: [31866441](https://pubmed.ncbi.nlm.nih.gov/31866441/) DOI: [10.1016/j.cmet.2019.11.018](https://doi.org/10.1016/j.cmet.2019.11.018)]
- Petrov MS, Taylor R. Intra-pancreatic fat deposition: bringing hidden fat to the fore. *Nat Rev Gastroenterol Hepatol* 2022; **19**: 153-168 [PMID: [34880411](https://pubmed.ncbi.nlm.nih.gov/34880411/) DOI: [10.1038/s41575-021-00551-0](https://doi.org/10.1038/s41575-021-00551-0)]
- Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. *Metabolism* 2017; **69**: 1-13 [PMID: [28285638](https://pubmed.ncbi.nlm.nih.gov/28285638/) DOI: [10.1016/j.metabol.2016.12.012](https://doi.org/10.1016/j.metabol.2016.12.012)]
- Yamazaki H, Tsuboya T, Katanuma A, Kodama Y, Tauchi S, Dohke M, Maguchi H. Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study. *Diabetes Care* 2016; **39**: 1677-1683 [PMID: [27422578](https://pubmed.ncbi.nlm.nih.gov/27422578/) DOI: [10.2337/dc16-0074](https://doi.org/10.2337/dc16-0074)]
- Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Yang WS, Chen MF, Wu MS. Increased Pancreatic Echogenicity with US: Relationship to Glycemic Progression and Incident Diabetes. *Radiology* 2018; **287**: 853-863 [PMID: [29613841](https://pubmed.ncbi.nlm.nih.gov/29613841/) DOI: [10.1148/radiol.2018170331](https://doi.org/10.1148/radiol.2018170331)]
- Chan TT, Tse YK, Lui RN, Wong GL, Chim AM, Kong AP, Woo J, Yeung DK, Abrigo JM, Chu WC, Wong VW, Tang RS. Fatty Pancreas Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. *Clin Gastroenterol Hepatol*

- 2022; **20**: 2014-2022.e4 [PMID: 34571257 DOI: 10.1016/j.cgh.2021.09.027]
- 17 **Yamazaki H**, Tauchi S, Wang J, Dohke M, Hanawa N, Kodama Y, Katanuma A, Saisho Y, Kamitani T, Fukuhara S, Yamamoto Y. Longitudinal association of fatty pancreas with the incidence of type-2 diabetes in lean individuals: a 6-year computed tomography-based cohort study. *J Gastroenterol* 2020; **55**: 712-721 [PMID: 32246380 DOI: 10.1007/s00535-020-01683-x]
- 18 **Macauley M**, Percival K, Thelwall PE, Hollingsworth KG, Taylor R. Altered volume, morphology and composition of the pancreas in type 2 diabetes. *PLoS One* 2015; **10**: e0126825 [PMID: 25950180 DOI: 10.1371/journal.pone.0126825]
- 19 **Al-Mrabeh A**, Hollingsworth KG, Steven S, Taylor R. Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity. *Diabetologia* 2016; **59**: 1753-1759 [PMID: 27179658 DOI: 10.1007/s00125-016-3984-6]
- 20 **Al-Mrabeh A**, Hollingsworth KG, Shaw JAM, McConnachie A, Sattar N, Lean MEJ, Taylor R. 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2020; **8**: 939-948 [PMID: 33031736 DOI: 10.1016/S2213-8587(20)30303-X]
- 21 **Szczepaniak LS**, Victor RG, Mathur R, Nelson MD, Szczepaniak EW, Tyer N, Chen I, Unger RH, Bergman RN, Lingvay I. Pancreatic steatosis and its relationship to  $\beta$ -cell dysfunction in humans: racial and ethnic variations. *Diabetes Care* 2012; **35**: 2377-2383 [PMID: 22968187 DOI: 10.2337/dc12-0701]
- 22 **Lu T**, Wang Y, Dou T, Xue B, Tan Y, Yang J. Pancreatic fat content is associated with  $\beta$ -cell function and insulin resistance in Chinese type 2 diabetes subjects. *Endocr J* 2019; **66**: 265-270 [PMID: 30700664 DOI: 10.1507/endocrj.EJ18-0436]
- 23 **Wen Y**, Chen C, Kong X, Xia Z, Kong W, Si K, Han P, Vivian Liu W, Li X. Pancreatic fat infiltration,  $\beta$ -cell function and insulin resistance: A study of the young patients with obesity. *Diabetes Res Clin Pract* 2022; **187**: 109860 [PMID: 35367311 DOI: 10.1016/j.diabres.2022.109860]
- 24 **Begovatz P**, Koliaki C, Weber K, Strassburger K, Nowotny B, Nowotny P, Müsigg K, Bunke J, Pacini G, Szendródi J, Roden M. Pancreatic adipose tissue infiltration, parenchymal steatosis and beta cell function in humans. *Diabetologia* 2015; **58**: 1646-1655 [PMID: 25740696 DOI: 10.1007/s00125-015-3544-5]
- 25 **Li YX**, Sang YQ, Sun Y, Liu XK, Geng HF, Zha M, Wang B, Teng F, Sun HJ, Wang Y, Qiu QQ, Zang X, Wu TT, Jones PM, Liang J, Xu W. Pancreatic Fat is not significantly correlated with  $\beta$ -cell Dysfunction in Patients with new-onset Type 2 Diabetes Mellitus using quantitative Computed Tomography. *Int J Med Sci* 2020; **17**: 1673-1682 [PMID: 32714070 DOI: 10.7150/ijms.46395]
- 26 **Skudder-Hill L**, Sequeira IR, Cho J, Ko J, Poppitt SD, Petrov MS. Fat Distribution Within the Pancreas According to Diabetes Status and Insulin Traits. *Diabetes* 2022; **71**: 1182-1192 [PMID: 35234845 DOI: 10.2337/db21-0976]
- 27 **Cao MJ**, Wu WJ, Chen JW, Fang XM, Ren Y, Zhu XW, Cheng HY, Tang QF. Quantification of ectopic fat storage in the liver and pancreas using six-point Dixon MRI and its association with insulin sensitivity and  $\beta$ -cell function in patients with central obesity. *Eur Radiol* 2023; **33**: 9213-9222 [PMID: 37410109 DOI: 10.1007/s00330-023-09856-x]
- 28 **Ishibashi C**, Kozawa J, Hosakawa Y, Yoneda S, Kimura T, Fujita Y, Fukui K, Iwahashi H, Shimomura I. Pancreatic fat is related to the longitudinal decrease in the increment of C-peptide in glucagon stimulation test in type 2 diabetes patients. *J Diabetes Investig* 2020; **11**: 80-87 [PMID: 31240874 DOI: 10.1111/jdi.13108]
- 29 **Steven S**, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B, Al-Mrabeh A, Daly AK, Batterham RL, Taylor R. Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes. *Diabetes Care* 2016; **39**: 158-165 [PMID: 26628414 DOI: 10.2337/dc15-0750]
- 30 **Zhyzhneuskaya SV**, Al-Mrabeh A, Peters C, Barnes A, Aribisala B, Hollingsworth KG, McConnachie A, Sattar N, Lean MEJ, Taylor R. Time Course of Normalization of Functional  $\beta$ -Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes. *Diabetes Care* 2020; **43**: 813-820 [PMID: 32060017 DOI: 10.2337/dc19-0371]
- 31 **Benito-Vicente A**, Jebari-Benslaiman S, Galicia-Garcia U, Larrea-Sebal A, Uribe KB, Martin C. Molecular mechanisms of lipotoxicity-induced pancreatic  $\beta$ -cell dysfunction. *Int Rev Cell Mol Biol* 2021; **359**: 357-402 [PMID: 33832653 DOI: 10.1016/bs.ircmb.2021.02.013]
- 32 **Sakai NS**, Taylor SA, Chouhan MD. Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat. *Br J Radiol* 2018; **91**: 20180267 [PMID: 29869917 DOI: 10.1259/bjr.20180267]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

